Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
LAMPRENE |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antileprosy. |
| Generic Name |
|
Clofazimine 50mg; soft gel caps. |
| Indications |
|
Lepromatous leprosy, including dapsone-resistant, and/or complicated by erythema nodosum leprosum. |
| Children |
|
Not recommended. |
| Adults |
|
Take with meals. Dapsone-resistant: 100mg daily with ≥1 other antileprosy drug for 3 years, then 100mg daily as monotherapy. Dapsone-sensitive: use triple-therapy for ≥2 years until skin smears negative, then use antileprosy monotherapy. Erythema nodosum: see literature. |
| Precautions |
|
GI disorders (eg, abdominal pain, diarrhea); if occurs, consider reducing dose, increasing dosing interval, or discontinuing. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Dapsone may inhibit antiinflammatory activity. |
| Adverse Reactions |
|
Skin discoloration (brown-black), ichthyosis, dryness, rash, pruritus, GI upset, abdominal/epigastric pain; eye, urine, fecal, sputum, or sweat discoloration, elevated blood glucose or ESR; rare: splenic infarction, bowel obstruction, GI bleeding, depression secondary to skin discoloration. |
| How Supplied |
|
Soft gel caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
